Article

Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistance

2021-02-24

Abstract excerpt

We have investigated how genomic distribution of chromatin accessibilities alter during acquisition of resistance to carboplatin-based chemotherapy using matched ovarian cell lines from high grade serous ovarian cancer (HGSOC) patients before and after becoming clinically resistant to platinum-based chemotherapy. Resistant lines show altered chromatin accessibility at intergenic regions, but less so at gene promot...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 92099542-5fcd-5bf1-9ff9-57188fad1bbf
DOI: 10.1101/2021.02.24.432641

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistanceDOI 10.1101/2021.02.24.432641Read

Chemosensitivity associated chromatin conformation changes and genomic cisplatin-DNA adduct distributionSemantic proximity Read

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancerSemantic proximity Read

Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancerSemantic proximity Read

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read

Gene networks and expression quantitative trait loci associated with platinum-based chemotherapy response in high-grade serous ovarian cancerSemantic proximity Read

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.Semantic proximity Read

Gene networks and expression quantitative trait loci associated with platinum-based chemotherapy response in high-grade serous ovarian cancerSemantic proximity Read

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read

Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic modelsSemantic proximity Read

Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancerSemantic proximity Read

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinomaSemantic proximity Read

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaSemantic proximity Read